$32.42
0.000.00%
Pre-Market: 4:24 PM EDT
Comments
Loading...
Supernus Pharmaceuticals Earnings Estimates, EPS & Revenue | NASDAQ:SUPN | Benzinga
Supernus Pharmaceuticals reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Earnings Date
May 7
EPS Estimate
$0.390
Quarterly Revenue Estimate
$143.45M
Annual Revenue
(as of Dec 31)
(as of Dec 31)
$661.82M
Analyze the earnings history of Supernus Pharmaceuticals using advanced sorting and filters.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPN | Supernus Pharmaceuticals | $0.00 | $0.39 | — | — | $143.64M | $143.45M | — | — | 05/07/2025 | Get Alert |
| SUPN | Supernus Pharmaceuticals | $0.39 | $0.52 | $0.27 | -48.08% | $164.31M | $155.25M | $174.16M | 12.18% | 02/25/2025 | Get Alert |
| SUPN | Supernus Pharmaceuticals | -$0.29 | $0.44 | $0.69 | 56.82% | $153.88M | $157.30M | $175.69M | 11.69% | 11/04/2024 | Get Alert |
| SUPN | Supernus Pharmaceuticals | -$0.02 | $0.39 | $0.36 | -7.69% | $135.56M | $148.85M | $168.32M | 13.08% | 08/06/2024 | Get Alert |
| SUPN | Supernus Pharmaceuticals | $0.29 | $0.38 | $0.00 | -100.00% | $153.76M | $145.83M | $143.64M | -1.50% | 05/08/2024 | Get Alert |
| SUPN | Supernus Pharmaceuticals | $0.43 | $0.55 | $0.39 | -29.09% | $167.33M | $155.03M | $164.31M | 5.99% | 02/27/2024 | Get Alert |
| SUPN | Supernus Pharmaceuticals | $0.03 | $0.13 | -$0.29 | -323.08% | $177.35M | $146.14M | $153.88M | 5.30% | 11/08/2023 | Get Alert |
| SUPN | Supernus Pharmaceuticals | $0.14 | -$0.23 | -$0.02 | 91.30% | $170.05M | $144.38M | $135.56M | -6.11% | 08/08/2023 | Get Alert |
| SUPN | Supernus Pharmaceuticals | $0.43 | $0.17 | $0.29 | 70.59% | $152.51M | $139.02M | $153.76M | 10.61% | 05/09/2023 | Get Alert |
| SUPN | Supernus Pharmaceuticals | $0.04 | $0.68 | $0.43 | -36.76% | $159.05M | $180.37M | $167.33M | -7.23% | 02/28/2023 | Get Alert |
| SUPN | Supernus Pharmaceuticals | $0.40 | $0.36 | $0.03 | -91.67% | $148.46M | $172.48M | $177.35M | 2.83% | 11/08/2022 | Get Alert |
| SUPN | Supernus Pharmaceuticals | $0.43 | $0.29 | $0.14 | -51.72% | $141.33M | $164.23M | $170.05M | 3.54% | 08/04/2022 | Get Alert |
| SUPN | Supernus Pharmaceuticals | $0.11 | — | $0.43 | — | $130.93M | — | $152.51M | — | 05/09/2022 | Get Alert |
| SUPN | Supernus Pharmaceuticals | $0.57 | $0.24 | $0.04 | -83.33% | $143.56M | $149.42M | $159.05M | 6.44% | 04/13/2022 | Get Alert |
| SUPN | Supernus Pharmaceuticals | $0.74 | $0.23 | $0.40 | 73.91% | $155.13M | $142.12M | $148.46M | 4.46% | 11/03/2021 | Get Alert |
| SUPN | Supernus Pharmaceuticals | $0.65 | $0.20 | $0.43 | 115.00% | $126.73M | $134.87M | $141.33M | 4.79% | 08/04/2021 | Get Alert |
| SUPN | Supernus Pharmaceuticals | $0.40 | $0.24 | $0.11 | -54.17% | $94.98M | $129.20M | $130.93M | 1.34% | 05/05/2021 | Get Alert |
| SUPN | Supernus Pharmaceuticals | $0.62 | $0.52 | $0.57 | 9.62% | $100.45M | $146.19M | $143.56M | -1.80% | 02/25/2021 | Get Alert |
| SUPN | Supernus Pharmaceuticals | $0.54 | $0.30 | $0.74 | 146.67% | $102.14M | $130.66M | $155.13M | 18.73% | 11/03/2020 | Get Alert |
| SUPN | Supernus Pharmaceuticals | $0.61 | $0.45 | $0.65 | 44.44% | $104.69M | $127.86M | $126.73M | -0.88% | 08/18/2020 | Get Alert |
| SUPN | Supernus Pharmaceuticals | $0.34 | $0.28 | $0.40 | 42.86% | $85.47M | $83.48M | $94.98M | 13.77% | 05/05/2020 | Get Alert |
Supernus Pharmaceuticals (SUPN) Earnings Per Share
Quarterly Earnings Surprise Amount
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q4 | 2025-02-25 | $0.27 | $0.52 | -48.1 % |
| Q3 | 2024-11-04 | $0.69 | $0.44 | 56.8 % |
| Q2 | 2024-08-06 | $0.36 | $0.39 | -7.69 % |
| Q1 | 2024-05-08 | $0 | $0.38 | -100.0 % |
Supernus Pharmaceuticals (SUPN) Revenue
Quarterly Revenue Surprise Amount
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q4 | 2025-02-25 | $174.16M | $155.25M | 12.2 % |
| Q3 | 2024-11-04 | $175.69M | $157.30M | 11.7 % |
| Q2 | 2024-08-06 | $168.33M | $148.85M | 13.1 % |
| Q1 | 2024-05-08 | $143.64M | $145.83M | -1.50 % |
FAQ
When is Supernus Pharmaceuticals (NASDAQ:SUPN) reporting earnings?
Supernus Pharmaceuticals (SUPN) is scheduled to report earnings on May 7, 2025. The last reported earnings were for reported on February 25, 2025 for Q4.
What were the latest earnings per share (EPS) for Supernus Pharmaceuticals (NASDAQ:SUPN)?
The Actual EPS was $0.27, which missed the estimate of $0.52.
What were Supernus Pharmaceuticals’s (NASDAQ:SUPN) revenues?
The Actual Revenue was $174.2M, which beat the estimate of $155.3M.
Browse earnings estimates, EPS, and revenue on all stocks.